Quantcast

Latest Savient Pharmaceuticals Inc. Stories

2011-04-21 15:05:00

EAST BRUNSWICK, N.J., April 21, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the company will release financial results for the first quarter 2011 prior to the open of the market on Thursday, May 5, 2011. John H. Johnson, Chief Executive Officer, and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call beginning at 9:00 a.m. Eastern Time on May 5, 2011, to discuss these results and to...

2011-03-08 15:10:00

EAST BRUNSWICK, N.J., March 8, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that Paul Hamelin, R.Ph., President of Savient will present at the ROTH 23rd Annual OC Growth Stock Conference on Tuesday, March 15, at 11:00 a.m. Pacific Time. The conference will be held at the Ritz-Carlton, Laguna Niguel in Dana Point, CA. A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com....

2011-03-02 15:10:00

EAST BRUNSWICK, N.J., March 2, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer of Savient will present at the 31st Annual Cowen & Co. Health Care Conference, on Monday, March 7, 2011, at 1:00 p.m. Eastern Time. The conference will be held at The Boston Marriott Copley Place in Boston, MA. A live webcast of the presentation can be accessed through the investor relations section of the Company's website...

2011-02-25 06:00:00

EAST BRUNSWICK, N.J. Feb. 25, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the official full U.S. commercial launch of KRYSTEXXA(TM) (pegloticase), which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic gout in adult patients refractory to conventional therapy. KRYSTEXXA is now the first and only therapy available to address this unmet medical need. "Since receiving FDA approval for KRYSTEXXA, we have...

2011-02-17 15:30:00

EAST BRUNSWICK, N.J., Feb. 17, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer of Savient will present at the Citi 2011 Global Healthcare Conference on Tuesday, March 1, 2011, at 4:00 p.m. Eastern Time. The conference will be held at the New York Hilton in New York, NY. A live webcast of the presentation can be accessed through the investor relations section of the Company's website www.savient.com....

2011-02-17 07:00:00

EAST BRUNSWICK, N.J., Feb. 17, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that its fourth quarter and year-end 2010 financial results will be released on Friday, February 25, 2011, at 7:00 a.m. Eastern Time. Following the announcement, John H. Johnson, Chief Executive Officer, and David Gionco, Group Vice President and Chief Financial Officer, will host an investment community conference call and webcast at 9:00 a.m. Eastern Time to review the...

2011-02-16 06:00:00

EAST BRUNSWICK, N.J., Feb. 16, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that it is strengthening its management team with three new executive appointments as it begins the commercial launch of KRYSTEXXA(TM). Louis Ferrari will join Savient as Senior Vice President, North America Commercial; Christine Mikail will join Savient as Senior Vice President, Corporate Development; and Stephen Davies will join Savient as Chief Information Officer and...

2011-02-04 15:10:00

EAST BRUNSWICK, N.J., Feb. 4, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the closing of its sale of $230 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes"). The aggregate principal amount of Notes sold reflects the full exercise by the underwriters of their option to purchase $30 million principal amount of Notes to cover over-allotments. The Notes are convertible, under certain circumstances and during...

2011-02-01 06:00:00

EAST BRUNSWICK, N.J., Feb. 1, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced it has priced $200 million aggregate principal amount of 4.75% Convertible Senior Notes due 2018 (the "Notes") pursuant to an automatically effective registration statement filed with the Securities and Exchange Commission on January 31, 2011. In addition, Savient has granted the underwriters an option to purchase up to an additional $30 million aggregate principal amount of...

2011-01-31 06:15:00

EAST BRUNSWICK, N.J., Jan. 31, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced its intention to offer, subject to market conditions and other factors, $125 million aggregate principal amount of Convertible Senior Notes due 2018 (the "Notes") pursuant to an automatically effective registration statement filed with the Securities and Exchange Commission today. Savient also intends to grant the underwriters an option to purchase up to an additional $18.75...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related